TICKERNERD
Menu
PTGXPTGXHealthcare · Biotechnology

PTGX Stock Forecast: Protagonist Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$155
+2.43% on the day

The 13 Wall Street analysts covering Protagonist Therapeutics, Inc. hold a median 12-month price target of $167 — +7.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 13 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$9.8B
Ticker Nerd rank
97 / 100
Median analyst target
$167
Analysts covering
13
Total return, dividends reinvested
1W
+6.3%
1M
+18.2%
YTD
+77.6%
1Y
+182.1%
From 52W high
0.0%
From 52W low
+182.1%
$55
$155
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PTGX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Protagonist Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Aug 2026
97 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
98
Momentum
95
Value
94
Growth
84
Quality
83
Revisions
77
Accruals
67
Issuance
54
Size
16

Volatility (98): The share price has been relatively steady.

Issuance (54): The company has been issuing shares or taking on financing, diluting existing holders.

Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PTGX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PTGX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200Oct 25Jan 26Apr 26Jul 26PTGXHigh $225Median $167Low $112

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says13 analysts
13 Buy0 Hold0 Sell
Low $112Median $167High $225

The green dot is the last close — the median target sits +7.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
10 Aug 2026Goldman SachsUpgradeBuy$110 → $186
10 Aug 2026Truist SecuritiesMaintainsBuy$145 → $170
10 Aug 2026WedbushMaintainsOutperform$118 → $173
6 Aug 2026BarclaysMaintainsOverweight$151 → $153
6 Aug 2026CitigroupMaintainsBuy$130 → $175
14 July 2026BarclaysMaintainsOverweight$119 → $151
14 July 2026BarclaysMaintainsOverweight—
7 July 2026Truist SecuritiesMaintainsBuy$121 → $145
7 July 2026Truist SecuritiesMaintainsBuy—
6 May 2026CitizensMaintainsMarket Outperform—
6 May 2026WedbushMaintainsOutperform—
15 Apr 2026Truist SecuritiesMaintainsBuy—
7 Apr 2026Clear StreetMaintainsBuy—
19 Mar 2026BarclaysMaintainsOverweight—
19 Mar 2026CitigroupMaintainsBuy—
19 Mar 2026JP MorganMaintainsOverweight—
19 Mar 2026Leerink PartnersMaintainsOutperform—
3 Mar 2026Goldman SachsMaintainsNeutral—
26 Feb 2026BarclaysMaintainsOverweight—
26 Feb 2026CitizensMaintainsMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PTGX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PTGX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+23.2%
Analysts raising
4
Analysts cutting
0
Fundamentals

Protagonist Therapeutics, Inc. (PTGX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
147.0×

Cheaper than 5% of US stocks

Price / sales
34.7×

Cheaper than 7% of US stocks

Price / book
11.6×

Cheaper than 9% of US stocks

EV / EBITDA
150.7×

Cheaper than 1% of US stocks

Growth & margins
Revenue growth (YoY)
3749.2%

Higher than 99% of US stocks

Earnings growth (YoY)
3749.2%

Higher than 99% of US stocks

Gross margin
—
Operating margin
74.4%

Higher than 99% of US stocks

Net margin
29.4%

Higher than 89% of US stocks

Returns & dividend
Return on equity
11.0%

Higher than 66% of US stocks

Return on assets
4.5%

Higher than 74% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PTGX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PTGXProtagonist Therapeutics, Inc.$9.8B
97
KRYSKrystal Biotech, Inc.$9.7B
78
KYMRKymera Therapeutics, Inc.$9.5B
75
PRAXPraxis Precision Medicines, Inc.$10.1B
51
APGEApogee Therapeutics, Inc.$10.1B
35
CYTKCytokinetics, Inc.$10.2B
47
IONSIonis Pharmaceuticals, Inc.$8.9B
48

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Protagonist Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PTGX news & analysis

Protagonist Therapeutics: "Strong Buy" ICOTYDE FDA Approval And PN-881 Advancement

Seeking Alpha · 12 Aug 2026positive

Protagonist Therapeutics maintains a "Strong Buy" rating following FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis, with strong partnership economics cited. The company is advancing rusfertide for polycythemia vera (with an FDA Priority Review decision expected August 2026) and planning phase 2b initiation of oral IL-17 antagonist PN-881 for Q1 2027.

Why it matters — PTGX watchers would care because the ICOTYDE FDA approval, rusfertide milestone/royalty potential with Takeda, and PN-881 pipeline progress represent key near-term catalysts for the company.

4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026

Zacks Investment Research · 11 Aug 2026neutral

Zacks Investment Research highlighted Protagonist Therapeutics alongside ALMS, ORKA and VNDA as a psoriasis drug stock to watch during Psoriasis Awareness Month 2026, noting the company offers diverse psoriasis opportunities spanning approved therapies, late-stage candidates and earlier-stage programs.

Why it matters — A PTGX watcher would care because the mention underscores the company's positioning in the psoriasis treatment landscape and could draw attention from investors screening for psoriasis-related drug developers.

Surging Earnings Estimates Signal Upside for Protagonist Therapeutics (PTGX) Stock

Zacks Investment Research · 7 Aug 2026positive

Protagonist Therapeutics (PTGX) shares have begun to gain and may continue moving higher in the near term, according to solid earnings estimate revisions highlighted by Zacks Investment Research.

Why it matters — A PTGX watcher would care because improving earnings estimate revisions are often viewed as a signal of potential near-term upside for the stock.

Protagonist Therapeutics (PTGX) Beats Q2 Earnings Estimates

Zacks Investment Research · 5 Aug 2026positive

Protagonist Therapeutics reported quarterly earnings of $2.29 per share, beating the Zacks Consensus Estimate of $2.11 per share. This marks a significant improvement from the loss of $0.55 per share recorded a year ago.

Why it matters — PTGX watchers would note that the company's quarterly earnings exceeded analyst expectations and swung strongly from a year-ago loss.

Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Accesswire · 5 Aug 2026positive

Protagonist Therapeutics reported second quarter 2026 financial results and a corporate update, citing strong early adoption of ICOTYDE in its first full quarter of commercial sales through its partner, an NDA for rusfertide under priority review for polycythemia vera (PDUFA date August 2026), a planned Phase 2b program for PN-881, and an initiated Phase 1 study for PN-477sc. The company reported $849.5 million in cash and marketable securities as of June 30, 2026.

Why it matters — The update signals commercial progress with ICOTYDE, an imminent regulatory decision on rusfertide, and a broad advancing pipeline, all backed by a sizable cash position.

FAQ

Frequently asked questions about PTGX stock

What is the PTGX stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Protagonist Therapeutics, Inc. have a median 12-month price target of $167, with estimates ranging from $112 to $225. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PTGX stock a buy right now?

Of the 13 analysts covering Protagonist Therapeutics, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Protagonist Therapeutics, Inc. 97 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PTGX?

As at 13 Aug 2026, Protagonist Therapeutics, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).

Will PTGX stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +7.7% from the last close, and Ticker Nerd's factor model ranks Protagonist Therapeutics, Inc. 97 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PTGX stock forecast for 2030?

No analyst covering Protagonist Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PTGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $112 to $225 over the next 12 months.

How has PTGX stock performed over the past year?

Protagonist Therapeutics, Inc. returned +182.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Protagonist Therapeutics, Inc. do?

Protagonist Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of peptide-based therapeutics using its proprietary technology platform.

What is the latest news on PTGX?

The most recent item we track (Seeking Alpha, 12 Aug 2026): "Protagonist Therapeutics: "Strong Buy" ICOTYDE FDA Approval And PN-881 Advancement". Protagonist Therapeutics maintains a "Strong Buy" rating following FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis, with strong partnership economics cited. The company is advancing rusfertide for polycythemia vera (with an FDA Priority Review decision expected August 2026) and planning phase 2b initiation of oral IL-17 antagonist PN-881 for Q1 2027.

Company

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company targets unmet medical needs in areas such as hematology, blood disorders, inflammation, immunology, and metabolic diseases. Key pipeline candidates include rusfertide, an injectable hepcidin mimetic in phase 3 clinical trials for polycythemia vera; icotrokinra (formerly JNJ-2113), an orally delivered investigational drug in phase 3 trials for plaque psoriasis and inflammatory diseases; and PN-943, an oral gut-restricted integrin antagonist that has completed phase 2 trials for ulcerative colitis. Additional programs encompass oral IL-17 antagonists like PN-881, obesity treatments, and iron metabolism disorders, advanced through internal efforts and collaborations with partners including Johnson & Johnson and Takeda. Protagonist Therapeutics Inc. plays a vital role in the biotechnology sector by pioneering oral peptide alternatives to injectable therapies for immune-mediated skin diseases and rare blood conditions. Founded in 2006 and headquartered in Newark, California, it focuses on advancing innovative treatments to improve patient outcomes in challenging therapeutic areas.

CEO Dr. Dinesh V. Patel Ph.D. · 141 employees · United States · https://www.protagonist-inc.com